Leuprorelin depot injection: patient considerations in the management of prostatic cancer
Authors Abouelfadel Z, Crawford ED
Published 11 April 2008 Volume 2008:4(2) Pages 513—526
Zinelabidine Abouelfadel1,2, E David Crawford1
1Urologic Oncology, University of Colorado Cancer Center, Aurora, CO, USA; 2Currently, Amiri Hospital Kuwait University, Urology Section, Kuwait City
Abstract: Hormone therapy is well established for treating patients with prostate cancer and remains the mainstay of the treatment of metastatic and locally advanced disease, this article reviews the rationale for its use, its different forms, and complications and controversies still surrounding some of its modalities. Availability of long-acting synthetic luteinizing hormone-releasing hormone (LHRH) agonists revolutionized the hormonal treatment of prostate cancer, and helped to avoid the emotional and psychological effects related to surgical castration. The depot formula has gained wide acceptance from both patients and physicians. This review emphasizes the newer, long-acting formula, leuprorelin (leuprolide acetate), especially the 6-month formula, its advantage over over shorter-acting depot products, and its potential to become a standard of care for patients eligible for androgen deprivation therapy.
Keywords: prostate cancer, androgen deprivation therapy (adt), leuprorelin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]